Fat-free mass index and apixaban exposure in frail hospitalized older adults: An exploratory study
Tancrède de Jerphanion, Olivier Brière, Jennifer Gautier, Alexis Bourgeais, Myriam Mellou, Léa Bourreau, Cédric Annweiler, Mathieu Corvaisier · 2026
Read Fat-free mass index and apixaban exposure in frail hospitalized older adults: An exploratory study by Tancrède de Jerphanion, Olivier Brière, Jennifer Gautier, Alexis Bourgeais, Myriam Mellou, Léa Bourreau, Cédric Annweiler, Mathieu Corvaisier (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13571488.txt.
Description
Tancrède de Jerphanion and co-authors report an exploratory study, published in 2026, on body composition and blood levels of a stroke prevention drug in frail older patients. Apixaban thins the blood, and kidney estimates based on creatinine can mislead when muscle mass is low. The team measured fat-free mass by an electrical body scan in hospital patients aged seventy-five and older.
Of more than three hundred patients screened, forty-three on the standard full dose had timed blood samples suitable for analysis. Lower fat-free mass tracked higher drug levels in a first pass, but the link faded once sex and kidney values were taken into account. The authors treat the signal as a question for larger studies, not a dosing rule.
Catalog record
| CREATOR | Tancrède de Jerphanion, Olivier Brière, Jennifer Gautier, Alexis Bourgeais, Myriam Mellou, Léa Bourreau, Cédric Annweiler, Mathieu Corvaisier |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |